Xenon Pharmaceuticals
XENE
59 hedge funds and large institutions have $234M invested in Xenon Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 9 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
189% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 9
180% more capital invested
Capital invested by funds: $83.6M → $234M (+$151M)
40% more funds holding
Funds holding: 42 → 59 (+17)
5.99% more ownership
Funds ownership: 64.37% → 70.37% (+6%)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$16.3M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$13.5M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$10.9M |
| 4 |
BC
Broadfin Capital
New York
|
+$10.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$8.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$5.39M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.51M |
| 3 |
IPC
Invesco Private Capital
New York
|
-$1.38M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$797K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$690K |
XENE Hedge Fund Activity: Q3 2018 in Review
59 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q3 2018, worth a combined $234M — up 180% from $83.6M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new XENE positions and 9 closed out — a net gain of 17 holders — while 11 added to existing stakes and 15 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $16.3M. The largest seller was Capital World Investors, cutting an estimated $5.39M.
- 59 institutional investors held Xenon Pharmaceuticals (XENE) as of Q3 2018, up from 42 in Q2 2018.
- Funds reported $234M of Xenon Pharmaceuticals stock for Q3 2018, up 180% quarter-over-quarter.
- 26 funds opened new Xenon Pharmaceuticals positions in Q3 2018 and 9 closed out, a net change of +17 holders.
- The largest Xenon Pharmaceuticals buyer in Q3 2018 was Vivo Capital, an estimated $16.3M added.
- The largest Xenon Pharmaceuticals seller in Q3 2018 was Capital World Investors, an estimated $5.39M sold.
Based on aggregated 13F filings for Q3 2018.